New SEC Form D filing

Merlin Biotech, Inc., 2026-08-11

A new SEC Form D private-offering notice from Doylestown, PA, a $50,000 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

Merlin Biotech, Inc. site↗ Verified via SEC Form D

mRNA biotechnology company developing cancer immunotherapies, spun out of the Baruch S. Blumberg Institute, with a lead program targeting solid tumors and Ewing sarcoma.

Filed 2026-08-11Filed to raise $50,000First money in 2026-06-30Raised so far $50,000HQ (as filed) Doylestown, PASector Biotech web-verified against the company’s own siteStage (inferred) Pre-seedCall status Debt-only offering
Source linked the Form D on EDGAR↗Website verified merlinbiotech.com↗Named in the filing 6 executives & directors
Open this row on the live feed →More new filings in Pennsylvania →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source